Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Oncol. Sep 15, 2026; 18(9): 121765
Published online Sep 15, 2026. doi: 10.4251/wjgo.121765
Published online Sep 15, 2026. doi: 10.4251/wjgo.121765
Chemotherapy regimens with immunotherapy in advanced gastric cancer: A prognostic study using Cox modeling
Shao-Wei Jiang, Department of Radiation Oncology, Qinghai University Affiliated Hospital, Xining 810000, Qinghai Province, China
Chen-Guang Zhang, Department of Otolaryngology, Qinghai University Affiliated Hospital, Xining 810000, Qinghai Province, China
Ke-Di Wang, Kun-Peng Shang, Department of Gastrointestinal Oncology, Qinghai University Affiliated Hospital, Qinghai University, School of Clinical Medicine, Xining 810000, Qinghai Province, China
Peng-Jie Yu, Department of Gastrointestinal Oncology, Qinghai University Affiliated Hospital, Xining 810000, Qinghai Province, China
Huan-Li Wang, Qinghai University Affiliated Hospital Tumor Day Chemotherapy Center, Qinghai University Affiliated Hospital, Xining 810000, Qinghai Province, China
Co-first authors: Shao-Wei Jiang and Chen-Guang Zhang.
Co-corresponding authors: Peng-Jie Yu and Huan-Li Wang.
Author contributions: Jiang SW and Zhang CG were responsible for conceptualization, investigation, methodology, software, formal analysis, project administration, resources, data curation, writing original draft as co-first authors; Wang KD was responsible for software, writing original draft; Shang KP was responsible for data curation, writing original draft; Yu PJ and Wang HL were responsible for writing review editing, visualization, validation, funding acquisition, supervision as co-corresponding authors.
Supported by Qinghai Provincial Science and Technology Program, No. 2023-ZJ-787.
Institutional review board statement: This study complied with the Declaration of Helsinki and was approved by the Ethics Committee of Qinghai University Affiliated Hospital (No. SL-2022-035)
Informed consent statement: All participants provided informed consent.
Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.
Data sharing statement: The data supporting the findings of this study are available from the corresponding author upon reasonable request, subject to institutional and ethical regulations.
Corresponding author: Huan-Li Wang, Professor, Qinghai University Affiliated Hospital Tumor Day Chemotherapy Center, Qinghai University Affiliated Hospital, No. 29 Tongren Road, Chengxi District, Xining 810000, Qinghai Province, China. 229572196@qq.com
Received: April 1, 2026
Revised: April 20, 2026
Accepted: June 2, 2026
Published online: September 15, 2026
Processing time: 147 Days and 7.3 Hours
Revised: April 20, 2026
Accepted: June 2, 2026
Published online: September 15, 2026
Processing time: 147 Days and 7.3 Hours
Core Tip
Core Tip: This study compares three commonly used neoadjuvant regimens (S-1 combined with oxaliplatin and sintilimab, plus oxaliplatin and S-1, and oxaliplatin plus leucovorin and fluorouracil) in advanced gastric cancer and demonstrates that the addition of a programmed cell death protein 1 inhibitor improves pathological response without increasing unacceptable toxicity. Furthermore, a prognostic model integrating treatment response (Response Evaluation Criteria in Solid Tumors 1.1 and tumor regression grade) with clinicopathological factors provides reliable prediction of progression-free survival, high